Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US based ConjuChem has started patient recruitment in a double-blind, randomized, placebo-controlled Phase 2 trial evaluating CJC-1134-PC in patients with type 2 diabetes mellitus who are receiving metformin monotherapy.
Subscribe to our email newsletter
The company expects to recruit around 225 patients in the study to investigate the efficacy and safety of weekly injections of CJC-1134-PC for 17 weeks.
The trial also aims to evaluate the pharmacokinetic and pharmacodynamic relationship of CJC-1134-PC and glycosylated hemoglobin (HbA1c) and/or fasting plasma glucose (FPG) in the trial.
ConjuChem CEO Patrick Soon-Shiong said positive results from this study will be a vital step in the fight against diabetes.